Paltusotine
Chemical compound
From Wikipedia, the free encyclopedia
Paltusotine, sold under the brand name Palsonify, is a medication used for the treatment of acromegaly.[1] It is a somatostatin receptor 2 agonist.[1] It is taken by mouth.[1] It was developed by Crinetics Pharmaceuticals.
Molecular structure of paltusotine | |
 3D representation of a paltusotine molecule | |
| Clinical data | |
|---|---|
| Trade names | Palsonify |
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a625106 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Somatostatin receptor agonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C27H22F2N4O |
| Molar mass | 456.497 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The most common side effects include diarrhea, abdominal pain, nausea, decreased appetite, bradycardia, hyperglycemia, and gastroenteritis (stomach inflammation).[2]
Paltusotine was approved for medical use in the United States in September 2025.[2]
Medical uses
Paltusotine is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.[1][2]
Acromegaly is a rare endocrine disorder that causes some bones, organs, and other tissue to grow bigger.[2] The pituitary gland in the brain causes these changes by making too much growth hormone due to the presence of a non-cancerous tumor.[2]
Adverse effects
Paltusotine increases the risk of cholelithiasis (gallstones); hyperglycemia (high blood sugar); hypoglycemia (low blood sugar); bradycardia (low heart rate); thyroid function abnormalities; steatorrhea (excessive fat in the stool) and malabsorption of dietary fats; and changes in vitamin B12 levels.[2]
The most common side effects are diarrhea, abdominal pain, nausea, decreased appetite, bradycardia, hyperglycemia, and gastroenteritis (stomach inflammation).[2]
History
The safety and efficacy of paltusotine were evaluated in two randomized, double-blind, placebo-controlled, phase III studies.[2]
In study 1, 111 adults with acromegaly received paltusotine or placebo.[2] The primary endpoint was the proportion of participants achieving biochemical control (defined as insulin-like growth factor [IGF-1] and GH levels within the normal range).[2] At 24 weeks, 56% of participants who received paltusotine had achieved biochemical control compared to 5% of participants who had received placebo.[2]
In study 2, 58 adults with acromegaly who were previously treated with and responded to other medical therapy received paltusotine or placebo.[2] At 36 weeks, 83% of participants switching to paltusotine in study 2 maintained biochemical control compared to 4% of participants receiving placebo.[2]
Society and culture
Legal status
Paltusotine was approved for medical use in the United States in September 2025.[3]
Names
Paltusotine is the international nonproprietary name.[4]
Paltusotine is sold under the brand name Palsonify.[1]
